Intracerebral Gene Therapy for Sanfilippo Type A Syndrome

An Open-label, Single Arm, Monocentric, Phase I/II Clinical Study of Intracerebral Administration of Adeno-associated Viral Vector Serotype 10 Carrying the Human SGSH and SUMF1 cDNAs for the Treatment of Sanfilippo Type A Syndrome.

The clinical trial P1-SAF-301 is an open-label, single arm, monocentric, phase I/II clinical study evaluating the tolerance and the safety of intracerebral administration of adeno-associated viral vector serotype 10 carrying the human SGSH and SUMF1 cDNAs for the treatment of Sanfilippo type A syndrome The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.

The primary objective is to assess the tolerance and the safety associated to the proposed treatment through a one-year follow up.

The secondary objective is to collect data to define exploratory tests that could become evaluation criteria for further clinical phase III efficacy studies.

Four patients will be included in the clinical trial and will be followed during one year.

The enrollment and the follow-up of the patients will take place at Bicêtre Hospital. The Neurosurgery will be performed at Necker-Enfants Malades Hospital.

Safety will be evaluating on clinical, radiological and biological parameters.

Study Overview

• Status: Completed
• Conditions: Mucopolysaccharidosis Type III A; Sanfilippo Disease Type A
• Intervention / Treatment: Genetic: SAF-301

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• France
  • Le Kremlin Bicêtre, France, 94275
    • Hôpital Bicêtre - Assistance Publique des Hôpitaux de Paris
  • Paris, France, 75015
    • Hôpital Necker, Assistance Publique des Hôpitaux de Paris

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 6 years (CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age: 18 (eighteen) months to end of 6 (six) years
• Onset of clinical manifestations related to MPSIIIA during the first 5 years of life
• SGSH activity in peripheral blood cell and / or cultured fibroblast extracts of less than 10% of controls.
• Patient affiliated to the French social security or assimilated regimens
• Family understanding the procedure and the informed consent
• Signed informed consent
• Vital laboratory parameters within normal range

Exclusion Criteria:

• Presence of brain atrophy on inclusion MRI judged on a cortico-dural distance of more than 1cm
• No independent walking (Ability to walk without help)
• Any condition that would contraindicate permanently anaesthesia
• Any other permanent medical condition not related to MPSIIIA
• Any vaccination 1 month before investigational drug administration
• Intake of aspirin within one month
• Any medication aiming at modifying the natural course of MPSIIIA given during the 6 months before vector injection
• Any condition that would contraindicate treatment with Prograf®, Modigraf®, Cellcept® and Solupred®

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: SAF-301	Genetic: SAF-301; The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerance and safety	Measured by; adverse events (by type and severity); clinical parameters (fever, seizure, headache, abnormal somnolence or lethargy, any new neurological symptoms),; radiological parameters (on MRI, any sign of bleeding after surgery, any hypersignal on T2 weighted images or diffusion images that are not at the points of injection, and any necrotic area evaluated through T1-weighted and diffusion imaging as well as modification of lipids in spectroscopy); biological parameters (in particular anemia, leucopenia, thrombopenia, liver dysfunction)	during the one year follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To collect data to define exploratory tests that could become evaluation criteria for further clinical phase III efficacy studies	Brain MRI; Neurocognitive/behavioral tests; Biological markers on blood, urine and CSF	during the one year follow-up

Collaborators and Investigators

• Sponsor: LYSOGENE

Study record dates

Study Major Dates

• Study Start: August 1, 2011
• Primary Completion (ACTUAL): May 1, 2013
• Study Completion (ACTUAL): May 1, 2013

Study Registration Dates

• First Submitted: November 10, 2011
• First Submitted That Met QC Criteria: November 15, 2011
• First Posted (ESTIMATE): November 18, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): May 6, 2014
• Last Update Submitted That Met QC Criteria: May 5, 2014
• Last Verified: May 1, 2014

More Information

Terms related to this study

• Keywords: Gene Therapy; Nervous System Diseases; Genetic Diseases, Inborn; Neurodegenerative Diseases; Metabolic Diseases; Adenovirus Associated Vector
• Additional Relevant MeSH Terms: Metabolic Diseases; Genetic Diseases, Inborn; Connective Tissue Diseases; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Mucinoses; Mucopolysaccharidoses; Mucopolysaccharidosis III
• Other Study ID Numbers: P1-SAF-301